DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Danaher - 5 Jim Cramer's - 5 Jim Cramer - 5 Jim - 5 we've - 3 Pavlo Gonchar - 3 Blair - 2 Beckman Coulter - 2
Top related locs:
Danaher Veralto China North America Europe bioprocessing Biotechnology Asia
Top related orgs:
CNBC - 5 Getty - 5 Management - 3 LSEG - 2 Biotechnology - 2 Deutsche Bank - 2 Bloomberg - 1 Revenue - 1

Search resuls for: "Danaher Corporation"


7 mentions found


☆ Danaher shares jump 7% as the turnaround in biotech spending finally arrives
  + stars: | 2024-04-23 | by ( Zev Fima | ) www.cnbc.com   time to read: +8 min
Shares of Danaher popped more than 7% on Tuesday after the life sciences company delivered beats across its three main businesses — a sign the long-awaited turnaround in the biotech industry is finally here. Danaher Why we own it : Danaher is a best-in-class life sciences and diagnostics company, with a management team who have proven time and again their ability to find new ways to grow. The turnaround is now in effect, with bioprocessing orders up on a sequential basis. Within the segment, bioprocessing sales fell a "high teens" percentage, while discovery and medical declined 20% year over year. Diagnostics sales advanced 7.5% on a core basis to $2.53 billion.
Persons: Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: LSEG, Bloomberg, Biotechnology, Management, CNBC, Getty Locations: bioprocessing, China, North America, Europe
☆ Danaher shares hit a 1-year high after earnings and we're increasing our price target
  + stars: | 2024-01-30 | by ( Zev Fima | ) www.cnbc.com   time to read: +10 min
DHR 1Y mountain Danaher 1 year Shares of Danaher rose as much as 5% to a 52-week high of $245.40 each. Core sales, not shown on the table, were down 22.5%. Core sales were down 4% year over year as strength from academic and life science research customers was more than offset by weakness from pharma and biopharma customers. Core sales fell about the same as strength in clinical diagnostics, driven by Beckman Coulter Diagnostics was more than offset by lower respiratory revenue at Cepheid. In this photo illustration, Danaher Corporation logo is seen displayed on a smartphone and PC screen.
Persons: we've, Danaher, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: Revenue, LSEG, JPMorgan Healthcare, Sciences, Diagnostics, Biotechnology, Management, pharma, Beckman Coulter Diagnostics, CNBC, Getty Locations: Danaher, China, Biotechnology, North America, Europe, Asia, Pacific, Cepheid
☆ Danaher's new acquisition is the latest sign the health-care firm is staging a quiet recovery
  + stars: | 2023-12-05 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +5 min
And with the company set to close a key acquisition this week, Danaher's stock is set up for a stronger 2024. On Tuesday, Danaher stock fell about 1.75%, to $218.25 per share. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Rainer Blair, Blair, Danaher, Jeff Marks, we've, Danaher's, Jim Cramer's, Jim Cramer, Jim, Igor Golovniov Organizations: British, Danaher, CNBC, Danaher Corporation, Lightrocket, Getty Locations: Danaher, Veralto
☆ It's time to get bullish on this health tech name, now that it's shed a drag on growth
  + stars: | 2023-10-04 | by ( Zev Fima | ) www.cnbc.com   time to read: +8 min
In the separation , we decided to keep the 173 shares of Veralto we received due to our ownership of 520 shares of Danaher. When we do that, we see a very favorable picture heading into next year and three reasons to be bullish. Veralto management is targeting long-term core growth in the mid-single-digit range on a percentage basis, whereas Danaher management sees ex-Veralto growth at a high-single-digit rate over the long term. So, as it stands we're already looking at a business that stands to see overall growth accelerate. It's also worth noting that our portfolio stands to benefit from any growth in the stand-alone shares of Veralto.
Persons: it's, —, haven't, let's, It's, they're, we'll, Danaher, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: Washington , D.C, Management, Deutsche Bank, Silicon Valley Bank, Federal Reserve, CNBC, Getty Locations: Veralto, Danaher, Washington ,, Silicon
☆ We're set to receive shares in Danaher's separated water business. Here's our plan for the new stock
  + stars: | 2023-09-29 | by ( Kevin Stankiewicz Jeff Marks | Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +9 min
Those potential returns can come from two places: Danaher stock and shares of Veralto (VLTO), the soon-to-be-standalone company that's in the business of water quality. When we receive Veralto shares on Monday, as all Danaher shareholders will, we intend to keep them, based on their current expected value. A "when-issued" market was established Wednesday for both Danaher and Veralto stock, providing a first look at how investors are valuing the companies on their own. Investors will receive one share in Veralto for every three shares of Danaher they own. The caveat is that spin-off debuts can see substantial volatility, and if Veralto shares were to receive a big pop, our discipline may require us to capitalize on that and take profits.
Persons: it's, Danaher, Jim Cramer, Jim Cramer's, Veralto, we'll, –, disinfect, That's, we've, attractively, We're, Jim, Pavlo Gonchar Organizations: Deutsche Bank, Zebra Technologies, CNBC, Getty Locations: Veralto, Danaher, DHR, Wells, York
☆ Danaher's stock drop looks like a buying opportunity after it reported a solid quarter
  + stars: | 2023-01-24 | by ( Zev Fima | ) www.cnbc.com   time to read: +7 min
When excluding the impact of declining Covid testing sales — but keeping in revenue from products that support vaccines and therapeutics — Danaher's base business saw core growth of 7.5%. Guidance Management expects overall core revenue growth to be down mid-single-digits on a percentage for the first quarter. For the full year 2023, management expects overall core revenue growth to be down mid-single-digits. Previously, only revenues related to Covid testing were excluded. On the call, management pointed to roughly 10% core revenue growth in both North America and Europe.
☆ Danaher's decision to spin off its water business is a win-win for long-term investors
  + stars: | 2022-09-15 | by ( Zev Fima | ) www.cnbc.com   time to read: +5 min
Danaher 's (DHR) announcement this week that it will spin off its growing water business is a big win for shareholders — including us at the Club. In both cases, after an initial growth hit due to the divestitures, we saw a notable sales growth acceleration once these slower growth business were on their own. More good news: Danaher's management team said 2022 core revenue growth is expected to be above the prior guidance range thanks higher-than-anticipated respiratory testing revenue at Cepheid. Base business core revenue growth is still expected to be up in the high-single-digit range. Whereas, they think EAS has a longer-term core revenue growth profile in the mid-single-digit range.
0 next >>
Total: 7